tivantinib arqule inc experimental small molecule anticancer drug bisindolylmaleimide binds dephosphorylated met kinase vitro met growth factor receptor tivantinib tested clinically highly selective met however mechanism action tivantinib still unclearcitation needed tivantinib displays cytotoxic activity via molecular mechanisms independent ability bind met notably tubulin binding likely underlies tivantinib possible applications include nonsmallcell lung carcinoma hepatocellular carcinoma oesophageal announced phase iii clinical trial advanced hepatocellular carcinoma failed meet primary antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikitivantinib